• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Regeneron's Evkeeza shows promise in curbing high triglycerides, but will genetic...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 16, 2021 at 11:32: PM
via When Regeneron scored an early approval for lipid lowering antibody Evkeeza back in February, the drugmaker cracked open a new pathway to lower abnormally high cholesterol levels. Now, Regeneron is chasing high triglycerides as well with some promising mid-stage data — but will genetic restrictions limit the drug’s use?

article source
 




Top Bottom
Back
Quote